- Home
- MIRM vs EVT Comparison
MIRM vs EVT Comparison
Compare MIRM & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- EVT
- Stock Information
- Founded
- MIRM 2018
- EVT 2003
- Country
- MIRM United States
- EVT United States
- Employees
- MIRM N/A
- EVT N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- EVT Finance Companies
- Sector
- MIRM Health Care
- EVT Finance
- Exchange
- MIRM Nasdaq
- EVT Nasdaq
- Market Cap
- MIRM 2.1B
- EVT 1.8B
- IPO Year
- MIRM 2019
- EVT N/A
- Fundamental
- Price
- MIRM $46.95
- EVT $24.41
- Analyst Decision
- MIRM Strong Buy
- EVT
- Analyst Count
- MIRM 11
- EVT 0
- Target Price
- MIRM $57.00
- EVT N/A
- AVG Volume (30 Days)
- MIRM 450.2K
- EVT 121.5K
- Earning Date
- MIRM 02-26-2025
- EVT 01-01-0001
- Dividend Yield
- MIRM N/A
- EVT 7.72%
- EPS Growth
- MIRM N/A
- EVT N/A
- EPS
- MIRM N/A
- EVT N/A
- Revenue
- MIRM $307,028,000.00
- EVT N/A
- Revenue This Year
- MIRM $82.14
- EVT N/A
- Revenue Next Year
- MIRM $26.18
- EVT N/A
- P/E Ratio
- MIRM N/A
- EVT N/A
- Revenue Growth
- MIRM 112.14
- EVT N/A
- 52 Week Low
- MIRM $23.14
- EVT $18.70
- 52 Week High
- MIRM $48.89
- EVT $23.82
- Technical
- Relative Strength Index (RSI)
- MIRM 65.98
- EVT 54.05
- Support Level
- MIRM $40.55
- EVT $23.63
- Resistance Level
- MIRM $47.25
- EVT $24.35
- Average True Range (ATR)
- MIRM 1.49
- EVT 0.29
- MACD
- MIRM 0.56
- EVT 0.07
- Stochastic Oscillator
- MIRM 95.52
- EVT 92.86
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.